Knorex gets NYSE American notice for failing continued listing equity standards
Reuters2026/08/26 21:00- Knorex received an NYSE American notice on Aug. 21, 2026 for failing continued listing standards tied to minimum stockholders’ equity.
- The exchange cited Sections 1003(a)(i) and (ii), which require $2 million-$4 million equity for issuers with multi-year losses.
- As of Dec. 31, 2025, stockholders’ deficit totaled $6.5 million; net losses were reported in each of the past four fiscal years.
- A compliance plan is due by Sept. 20, 2026, targeting a return to compliance by Feb. 21, 2028.
- The notice does not trigger an immediate delisting; shares continue trading on NYSE American subject to other requirements.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Most panda coin types from the 2026 edition steadily rebounded in August
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage
Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.
2-Yr Benchmark Govt Yields - Germany vs Other Nations
2-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
